Bioharvest Sciences Inc. BHST
· data as of November 13, 2026
Bioharvest Sciences Inc. (BHST) is a company listed in the US with a market value of about $34M. In the twelve months to September 30, 2026 it had revenue of $34M and net income of -$12M, a net margin of -34.7%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -78%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 3% below the current price.
About Bioharvest Sciences
Bioharvest Sciences is listed in the US. It was profitable in 0 of the last 3 years in our data.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $34M | $35M | $25M | $13M |
| Net income | -$12M | -$11M | -$13M | -$13M |
| Free cash flow | — | -$10M | -$10M | -$10M |
| EPS (diluted) | $-0.56 | $-0.49 | $-0.57 | $-0.55 |
| Net margin | -34.7% | -32.3% | -51.3% | -99.2% |
| ROIC | — | -21.6% | -133.4% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 4 analysts is $9.25, 515% above the current price; targets range from $5.00 to $14.00; the consensus rating is “Strong buy”; expected EPS is $-0.55 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Bioharvest Sciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 3% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Bioharvest Sciences pay a dividend?
Not currently.
Is Bioharvest Sciences a good stock to buy?
We do not give buy or sell advice. Bioharvest Sciences scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.